Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform study of iscalimab and LYS006 in moderate to severe hidradenitis suppurativa
2018-002757-30Phase 2Active
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing iscalimab, LYS006 and placebo (3 arms). Primary endpoint: Hidradenitis suppurativa clinical response at week 16. Started Jan 2019; status: active.
02
Drugs
iscalimabLYS006
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2018-002757-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002757-30.